Alfa bloccanti

<p>Applications An α2-Adrenergic blocker; analogue of Mianserin. Antidepressant.<br>References De Boer, T., et al.: Neuropharmacology, 27, 399 (1988), Smith, W.T., et al.: Psychopharmacol. Bull., 26, 191 (1990)<br></p>

<p>Stability Hygroscopic<br>Applications Semicarbazide Hydrochloride is a metabolite of Nitrofuran (N493840), a minor antimicrobial used in veterinary medicine affecting semicarbazide-sensitive amine oxidase (SSAO) activity (1). Semicarbazide may be found in from nitrofuran residues in honey extracts (2) as well as milk from dairy cows (3). Drinking water contaminant candidate list 3 (CCL 3) compound as per United States Environmental Protection Agency (EPA), environmental, and food contaminants.Environmental contaminants; Food contaminants; Heat processing contaminants.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References 1. Elliott J. et al.: J Pharm Pharmacol. 1989 Jan;41(1):37-41. 2. Tribalat L. et al.: Anal Bioanal Chem. 2006 Dec;386(7-8):2161-8. 3. Chu, P. et al.: J. Agric. Food Chem. 2007 Feb:55(6);2129-2135<br></p>

<p>Applications N,N-Diethylcyanoacetamide (cas# 26391-06-0) is a compound useful in organic synthesis.<br></p>

<p>Applications A metabolite of Mirtazapine, α2-adrenergic blocker.<br>References De Boer, T., et al.: Neuropharmacology, 27, 399 (1988), Smith, W.T., et al.: Psychopharmacol. Bull., 26, 191 (1990)<br></p>

<p>Applications 1-Bromo-3-chloropropane can be used safer and equally efficient alternative to chloroform as a phase-separation agent in the 1-step method of RNA isolation from biological samples such as animal and plant tissue.<br>References Chomczynski, P. et al.: Anal. Biochem., 225, 163 (1995); Chey, S. et al.: Anal. Biochem., 411, 164 (2011);<br></p>

Alfuzosin (SL 77499) is an alpha-1 adrenergic antagonist used to treat benign prostatic hypertrophy and urethral dysfunction.

<p>Applications (R)-Tamsulosin-d4 Hydrochloride is the labeled analogue of (R)-Tamsulosin Hydrochloride (T006350), a specific α1-adrenoceptor antagonist. It is used in the treatment of benign prostatic hypertrophy.<br>References Kawabe, K., et al.: J. Urol., 144, 908 (1990); Abrams, P., et al.: Br. J. Urol., 76, 325 (1995); Michel, M.C., Expert Opin. Pharmacother., 5, 151 (2004)<br></p>

<p>Impurity Trazodone Deschloro Impurity<br>Stability Hygroscopic<br>Applications A Trazodone (T718500) impurity. An antipsychotic with potential use as a schizophrenia agent. Trazodone impurity B.<br>References Pai, N. et al.: J. Chem Pharmaceut. Res., 2, 458 (2010); Silvestrini, B., et al.: Eur. J. Pharmacol., 12, 231 (1970); Brogden, R.N., et al.: Drugs, 21, 401 (1981);<br></p>

<p>Impurity Mirtazapine EP Impurity F<br>Applications 10-Oxo Mirtazapine (Mirtazapine Impurity F) is an impurity of Mirtazapine. Mirtazapine EP Impurity F.<br>References De Boer, T., et al.: Neuropharmacol., 27, 399 (1988), Vindevogel, J., et al.: Anal. Chem., 63, 1530 (1991), Wynia, G., et al.: J. Chromatogr., 773, 339 (1997),<br></p>

<p>Applications A carvedilol Impurity.<br></p>

<p>Applications An impurity in the synthesis of Silodosin (S465000), an α1a-adrenoceptor antagonist. It is used in treatment of benign prostatic hypertophy.<br>References Barve, I. et al.: Tetra., 69, 2834 (2013); Shibata, K., et al.: Mol. Pharmacol., 48, 250 (1995), Murata, S., et al.: J. Urol., 164, 578 (2000),<br></p>

<p>Applications An optically active metabolite of Carvedilol (C184625), a nonselective ß-adrenergic blocker with α1-blocking activity.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., ET AL.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Schaefer, W.H., et al.: Drug Metab. Dispos., 26, 10, 958 (1998),<br></p>

<p>Impurity Mirtazapine EP Impurity C; Mirtazapine USP Related Compound C<br>Applications 1-Oxo Mirtazapine (Mirtazapine Impurity C; Mirtazapine USP Related Compound C) is an impurity of Mirtazapine. Mirtazapine EP Impurity C.<br>References De Boer, T., et al.: Neuropharmacol., 27, 399 (1988), Vindevogel, J., et al.: Anal. Chem., 63, 1530 (1991), Wynia, G., et al.: J. Chromatogr., 773, 339 (1997),<br></p>

<p>Impurity Mirtazapine<br>Applications A labelled metabolite of Mirtazapine, α2-adrenergic blocker.<br>References De Boer, T., et al.: Neuropharmacology, 27, 399 (1988), Smith, W.T., et al.: Psychopharmacol. Bull., 26, 191 (1990)<br></p>

<p>Applications 2-(2-Aminoethoxy)anisole is used as an additive to vinylphosphonic acid esters and acrylonitrile forming compounds displaying hypotensive activity. An impurity from the process of Carvedilol (C184625)<br>References Reznik, V. et al.: Russ. Chem. Bull., 48, 979, (1999); Hirohashi, M., et al.: Arzneim.-Forsch., 40, 735 (1990), Packer, M., et al.: N. Engl. J. Med., 334, 1349 (1996),<br></p>

<p>Applications A metabolite of Carvedilol (C184625). It is used in the treatment of hypertension.<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., ET AL.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Schaefer, W.H., et al.: Drug Metab. Dispos., 26, 10, 958 (1998),<br></p>

<p>Applications 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl Methanesulfonate is an intermediate of Silodosin (S465000) which is an α1a-adrenoceptor antagonist and used in the treatment of benign prostatic hypertophy.<br>References Francesco, C., et al.: Eur. J. Org. Chem., 27, 6011 (2015)<br></p>

<p>Impurity Tamsulosin EP Impurity A<br>Applications N-[2-(2-Ethoxyphenoxy)ethyl]-(R)-Tamsulosin (Tamsulosin EP Impurity A) is derived from 5-[(2R)-2-Aminopropyl]-2-methoxybenzenesulfonamide (A628695), which is a precursor in the synthesis of Tamsulosin (T006350) and other alpha-andregenic antagonists. (R)-Tamsulosin is a specific α1-adrenoceptor antagonist. It is used in the treatment of benign prostatic hypertrophy.<br>References Kawabe, K., et al.: J. Urol., 144, 908 (1990), Abrams, P., et al.: Br. J. Urol., 76, 325 (1995), Michel, M.C., Expert Opin. Pharmacother., 5, 151 (2004),<br></p>